Steven Lichtman
Stock Analyst at Oppenheimer
(2.99)
# 1,339
Out of 5,114 analysts
71
Total ratings
39.22%
Success rate
13.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $22.07 | -0.32% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $289.62 | +26.03% | 7 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $95.61 | +30.74% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $66.06 | +54.41% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $89.13 | +51.46% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $5.84 | +105.48% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $79.97 | +37.55% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $98.63 | -4.69% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $12.03 | +440.32% | 8 | Aug 6, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $17.11 | -35.71% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $13.37 | -10.25% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $87.70 | -0.80% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.34 | +926.39% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $355.20 | -18.92% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $116.22 | -9.65% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $25.14 | +496.66% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $82.75 | +2.72% | 3 | Sep 4, 2020 |
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $22.07
Upside: -0.32%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $289.62
Upside: +26.03%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $95.61
Upside: +30.74%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $66.06
Upside: +54.41%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $89.13
Upside: +51.46%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $5.84
Upside: +105.48%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $79.97
Upside: +37.55%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $98.63
Upside: -4.69%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $12.03
Upside: +440.32%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $17.11
Upside: -35.71%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $13.37
Upside: -10.25%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $87.70
Upside: -0.80%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.34
Upside: +926.39%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $355.20
Upside: -18.92%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $116.22
Upside: -9.65%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $25.14
Upside: +496.66%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $82.75
Upside: +2.72%